, Registre français des traitements de suppléance de l'insuffisance rénale chronique, Agence de la Biomédecine, 2017.
Obesity: global epidemiology and pathogenesis, Nat Rev Endocrinol, vol.15, issue.5, pp.288-298, 2019. ,
Differential association of body mass index with access to kidney transplantation in men and women, clin j am soc nephrol, vol.9, issue.5, pp.951-959, 2014. ,
Kidney transplantation significantly improves patient and graft survival irrespective of BMI: A cohort study, Am J Transplant, vol.15, issue.9, pp.2378-2386, 2015. ,
Obesity and access to kidney transplantation in patients starting dialysis: A prospective cohort study, PLoS ONE, vol.12, issue.5, p.176616, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01604887
Kidney transplantation in obese patients, World J Transplant, vol.6, issue.1, pp.135-143, 2016. ,
Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, pp.13-141, 2015. ,
, Effects of Obesity on Kidney Transplantation Outcomes: A Systematic Review and Meta-Analysis. Transplantation, vol.98, issue.2, pp.167-176, 2014.
The Survival Benefit of Kidney Transplantation in Obese Patients, Am J Transplant, vol.13, issue.8, pp.2083-2090, 2013. ,
A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients, Transplantation, vol.80, issue.1, pp.41-46, 2005. ,
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation, Clin Pharmacokinet, vol.43, issue.10, pp.623-653, 2004. ,
Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients, Expert Opin Drug Metab Toxicol, vol.13, issue.12, pp.1225-1236, 2017. ,
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus multicenter renal study group, Transplantation, vol.64, issue.3, pp.436-443, 1997. ,
Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity, Transplantation, vol.91, issue.10, pp.1098-1102, 2011. ,
Tacrolimus-induced neurotoxicity in kidney transplant recipients, Transplant Proc, vol.34, issue.8, pp.3188-3190, 2002. ,
Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine, Transplantation, vol.65, issue.3, pp.446-449, 1998. ,
A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation, Drugs, vol.46, issue.4, pp.746-794, 1993. ,
A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients, Ther Drug Monit, vol.32, issue.6, pp.708-714, 2010. ,
A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients, Br J Clin Pharmacol, vol.85, issue.3, pp.601-615, 2019. ,
Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing, Clin Pharmacol Ther, vol.98, issue.1, pp.19-24, 2015. ,
Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy, Transplantation, vol.74, issue.10, pp.1419-1424, 2002. ,
Importance of hematocrit for a tacrolimus target concentration strategy, Eur J Clin Pharmacol, vol.70, issue.1, pp.65-77, 2014. ,
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling, Br J Clin Pharmacol, vol.78, issue.3, pp.509-523, 2014. ,
Implications of obesity for drug therapy: limitations and challenges, Clin Pharmacol Ther, vol.90, issue.1, pp.77-89, 2011. ,
Mechanisms of lower maintenance dose of tacrolimus in obese patients, Drug Metab Pharmacokinet, vol.29, issue.4, pp.341-347, 2014. ,
High initial blood levels of tacrolimus in overweight renal transplant recipients, Transplant Proc, vol.37, issue.3, pp.1453-1454, 2005. ,
Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose, Transplant Direct, vol.3, issue.2, p.129, 2017. ,
Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients, Eur J Clin Pharmacol, vol.24, issue.5, pp.643-647, 1983. ,
Gentamicin therapy, Drug Intell Clin Pharm, vol.8, pp.650-655, 1974. ,
Effects of obesity on pharmacokinetics implications for drug therapy, Clin Pharmacokinet, vol.39, issue.3, pp.215-231, 2000. ,
The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients, Transplantation, vol.47, issue.5, pp.806-810, 1989. ,
Influence of overweight on survival of kidney transplant, Nephrol Dial Transplant, vol.12, issue.4, p.855, 1997. ,
The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation, Eur J Clin Pharmacol, vol.68, issue.5, pp.671-680, 2012. ,
Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants, Kidney Res Clin Pract, vol.31, issue.3, pp.157-162, 2012. ,
Which kidney transplant recipients can benefit from the initial tacrolimus dose reduction?, Biomed Res Int, p.4573452, 2018. ,
Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers, Clin Pharmacokinet, vol.53, issue.10, pp.931-941, 2014. ,
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid, J Clin Endocrinol Metab, vol.83, issue.3, pp.847-850, 1998. ,
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase, J Clin Invest, vol.95, issue.5, pp.2111-2119, 1995. ,
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects, Clin Pharmacol Ther, vol.93, issue.3, pp.275-282, 2013. ,
Disease-induced variations in plasma protein levels, Clin Pharmacokinet, vol.19, issue.3, pp.218-229, 1990. ,
Absorption, distribution and excretion of tacrolimus (FK506) in the baboon, Drug Metab Pharmacokinet, vol.13, issue.5, pp.478-483, 1998. ,
Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the Rat, Drug Metab Pharmacokinet, vol.13, issue.3, pp.259-265, 1998. ,
Impact of obesity on drug metabolism and elimination in adults and children, Clin Pharmacokinet, vol.51, issue.5, pp.277-304, 2012. ,
Significant weight reduction in obese subjects enhances carbamazepine elimination, Clin Pharmacol Ther, vol.51, issue.5, pp.501-506, 1992. ,
Optimization of initial tacrolimus dose using pharmacogenetic testing, Clin Pharmacol Ther, vol.87, issue.6, pp.721-726, 2010. ,
Dosing equation for tacrolimus using genetic variants and clinical factors, Br J Clin Pharmacol, vol.72, issue.6, pp.948-957, 2011. ,
Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients, Eur J Clin Pharmacol, vol.69, issue.1, pp.53-63, 2013. ,
Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study, Clin Transplant, vol.27, issue.3, pp.272-281, 2013. ,
A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: A population approach, Clin Pharmacokinet, vol.56, issue.8, pp.963-975, 2017. ,
Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose, Ther Drug Monit, vol.36, issue.1, pp.62-70, 2014. ,
Body mass index, muscle and fat in chronic kidney disease: questions about survival, Nephrol Dial Transplant, vol.23, issue.8, pp.2461-2466, 2008. ,
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation, Nephrol Dial Transplant, vol.18, issue.11, pp.2409-2414, 2003. ,
Therapeutic drug monitoring of tacrolimus: a moving matter, Therapie, vol.57, issue.2, pp.133-136, 2002. ,
REFERENCES 1. Rapport annuel REIN 2017, Registre français des traitements de suppléance de l'insuffisance rénale chronique, Agence de la Biomédecine, Aliment Pharmacol Ther, vol.22, issue.1, pp.37-44, 2005. ,
Kidney transplantation in obese patients, World J Transplant, vol.6, issue.1, pp.135-143, 2016. ,
Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, vol.13, p.141, 2015. ,
Effects of Obesity on Kidney Transplantation Outcomes: A Systematic Review and Meta-Analysis, Transplantation, vol.98, issue.2, pp.167-176, 2014. ,
The Survival Benefit of Kidney Transplantation in Obese Patients, American Journal of Transplantation, vol.13, issue.8, pp.2083-2090, 2013. ,
Kidney Transplantation Significantly Improves Patient and Graft Survival Irrespective of BMI: A Cohort Study, Am J Transplant, vol.15, issue.9, pp.2378-2386, 2015. ,
A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients, Transplantation, vol.80, issue.1, pp.41-46, 2005. ,
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group, Transplantation, vol.64, issue.3, pp.436-443, 1997. ,
Expression of CYP3A5 and Pglycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity, Transplantation, vol.91, issue.10, p.1098, 2011. ,
Tacrolimus-induced neurotoxicity in kidney transplant recipients, Transplant Proc, vol.34, issue.8, pp.3188-3190, 2002. ,
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation, Clin Pharmacokinet, vol.43, issue.10, pp.623-653, 2004. ,
A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation, Drugs, vol.46, issue.4, pp.746-794, 1993. ,
A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients, Ther Drug Monit, vol.32, issue.6, pp.708-714, 2010. ,
Mechanisms of lower maintenance dose of tacrolimus in obese patients, Drug Metab Pharmacokinet, vol.29, issue.4, pp.341-347, 2014. ,
High initial blood levels of tacrolimus in overweight renal transplant recipients, Transplant Proc, vol.37, issue.3, pp.1453-1454, 2005. ,
Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose, Transplant Direct, vol.3, issue.2, 2017. ,
Kidney and Pancreas Transplantation in the United States, American Journal of Transplantation, vol.6, issue.5p2, pp.1153-1169, 1995. ,
Choosing between immunity and tolerance after transplantation, Cellular Immunology, vol.248, issue.1, pp.44-47, 2007. ,
Innate alloimmunity: history and current knowledge, Exp Clin Transplant, vol.5, issue.1, pp.575-584, 2007. ,
Rejet de la greffe rénale : mécanisme et prévention, Néphrologie & Thérapeutique, vol.7, issue.1, pp.18-26, 2011. ,
Analysis of HLA class I specific antibodies in patients with failed allografts, Transplantation, vol.83, issue.1, pp.54-61, 2007. ,
Humoral theory of transplantation: mechanism, prevention, and treatment, Hum Immunol, vol.66, issue.4, pp.334-342, 2005. ,
Biologics in the prevention and treatment of graft rejection, Springer Semin Immunopathol, vol.27, issue.4, pp.457-476, 2006. ,
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics, J Antibiot, vol.40, issue.9, pp.1249-1255, 1987. ,
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J Antibiot, vol.40, issue.9, pp.1256-1265, 1987. ,
Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis, Saudi Journal of Kidney Diseases and Transplantation, vol.29, issue.6, p.1376, 2018. ,
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials, Eur J Clin Pharmacol, vol.66, issue.12, pp.1177-1187, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00627922
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A, Nature, vol.352, issue.6338, pp.803-807, 1991. ,
Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation, Nature, vol.357, issue.6380, pp.695-697, 1992. ,
FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin, Nature, vol.357, issue.6380, pp.692-694, 1992. ,
Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, issue.26, pp.2715-2729, 2004. ,
Clinical pharmacokinetics of tacrolimus, Clin Pharmacokinet, vol.29, issue.6, pp.404-430, 1995. ,
Large within-day variation in cyclosporine absorption: circadian variation or food effect?, Clin J Am Soc Nephrol, vol.1, issue.3, pp.462-466, 2006. ,
Pharmacokinetics of tacrolimus in liver transplant patients, Clin Pharmacol Ther, vol.57, issue.3, pp.281-290, 1995. ,
Absorption, Distribution, Metabolism and Excretion of Tacrolimus(FK506) in the Rat, Drug Metabolism and Pharmacokinetics, vol.13, issue.3, pp.259-265, 1998. ,
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation, Clin Pharmacokinet, vol.53, issue.2, pp.123-139, 2014. ,
Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS, Ther Drug Monit, vol.34, issue.2, pp.134-142, 2012. ,
Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics, Drug Metab Pharmacokinet, vol.22, issue.5, pp.328-335, 2007. ,
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects, Drug Metab Dispos, vol.27, issue.6, pp.633-636, 1999. ,
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin Pharmacol Ther, vol.62, issue.1, pp.41-49, 1997. ,
Renal allograft dysfunction associated with rifampin-tacrolimus interaction, Ann Pharmacother, vol.34, issue.1, pp.27-31, 2000. ,
The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats, Adv Clin Exp Med, vol.25, issue.2, pp.237-242, 2016. ,
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J Clin Invest, vol.80, issue.4, pp.1029-1036, 1987. ,
Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann Pharmacother, vol.42, issue.7, pp.1037-1047, 2008. ,
Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids, Br J Clin Pharmacol, vol.56, issue.3, pp.327-330, 2003. ,
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation, Nephrol Dial Transplant, vol.18, issue.11, pp.2409-2414, 2003. ,
Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5, Curr Drug Metab, vol.9, issue.1, pp.20-33, 2008. ,
Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs, Drug Metab Dispos, vol.32, issue.10, pp.1083-1091, 2004. ,
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients, Clin Pharmacol Ther, vol.92, issue.3, pp.366-375, 2012. ,
The genetic determinants of the CYP3A5 polymorphism, Pharmacogenetics, vol.11, issue.9, pp.773-779, 2001. ,
Genetic contribution to variable human CYP3A-mediated metabolism, Adv Drug Deliv Rev, vol.54, issue.10, pp.1271-1294, 2002. ,
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, vol.27, issue.4, pp.383-391, 2001. ,
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing, Clinical Pharmacology & Therapeutics. Published, pp.19-24, 2018. ,
Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis, PLoS One, vol.10, issue.6, 2015. ,
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients, Clin Pharmacol Ther, vol.82, issue.6, pp.711-725, 2007. ,
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin Pharmacol Ther, vol.74, issue.3, pp.245-254, 2003. ,
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing, Pharmacogenet Genomics, vol.26, issue.1, pp.40-43, 2016. ,
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenomics, vol.12, issue.10, pp.1383-1396, 2011. ,
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients, Pharmacogenomics, vol.14, issue.9, pp.1027-1036, 2013. ,
A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients, British Journal of Clinical Pharmacology, vol.85, issue.3, pp.601-615, 2019. ,
Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance, Clin Pharmacol Ther, vol.95, issue.4, pp.416-422, 2014. ,
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine, Clin Pharmacol Ther, vol.62, issue.3, pp.248-260, 1997. ,
Interindividual variation in expression of Pglycoprotein in normal human liver and secondary hepatic neoplasms, J Pharmacol Exp Ther, vol.275, issue.2, pp.1011-1018, 1995. ,
Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity -implications for mechanistic pharmacokinetics modeling, Sci Rep, vol.9, issue.1, p.10505, 2019. ,
Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus, Ther Drug Monit, vol.35, issue.4, pp.459-465, 2013. ,
,
, ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation, Clin Chim Acta, vol.413, pp.1326-1337, 2012.
P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity, Expert Opin Drug Metab Toxicol, vol.4, issue.4, pp.439-452, 2008. ,
Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, Proc Natl Acad Sci, vol.105, issue.5, pp.1733-1738, 2008. ,
Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients, Ther Drug Monit, vol.36, issue.1, pp.71-79, 2014. ,
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients, Eur J Clin Pharmacol, vol.70, issue.6, pp.685-693, 2014. ,
Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers, Eur J Clin Pharmacol, vol.69, issue.4, pp.807-812, 2013. ,
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.12, issue.5, pp.555-565, 2016. ,
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo, Clin Pharmacol Ther, vol.91, issue.6, pp.1044-1052, 2012. ,
A Rationale for Age-Adapted Immunosuppression in Organ Transplantation, Transplantation, vol.99, issue.11, pp.2258-2268, 2015. ,
Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients, Transplant Rev (Orlando), vol.29, issue.4, pp.224-230, 2015. ,
Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver, Biochem Pharmacol, vol.50, issue.5, pp.727-730, 1995. ,
Demographic considerations in tacrolimus pharmacokinetics, Transplant Proc, vol.30, issue.4, pp.1359-1364, 1998. ,
Time-related clinical determinants of longterm tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients, Clin Pharmacokinet, vol.43, issue.11, pp.741-762, 2004. ,
How important are gender differences in pharmacokinetics?, Clin Pharmacokinet, vol.41, issue.5, pp.329-342, 2002. ,
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.12, issue.5, pp.555-565, 2016. ,
Genetic variability in CYP3A5 and its possible consequences, Pharmacogenomics, vol.5, issue.3, pp.243-272, 2004. ,
Drugs as CYP3A Probes, Inducers, and Inhibitors, Drug Metabolism Reviews, vol.39, issue.4, pp.699-721, 2007. ,
Cytochrome P450 variations in different ethnic populations, Expert Opinion on Drug Metabolism & Toxicology, vol.8, issue.3, pp.371-382, 2012. ,
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients, Clin Chem, vol.57, issue.11, pp.1574-1583, 2011. ,
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, Pharmacogenomics J, vol.11, issue.4, pp.274-286, 2011. ,
ABCB1 single nucleotide polymorphisms in the Brazilian population, Mol Biol Rep, vol.37, issue.1, pp.111-118, 2010. ,
Therapeutic drug monitoring of tacrolimus: a moving matter, Therapie, vol.57, issue.2, pp.133-136, 2002. ,
Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients, Aliment Pharmacol Ther, vol.22, issue.1, pp.37-44, 2005. ,
Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation, PLOS ONE, vol.10, issue.3, p.122399, 2015. ,
Non-adherence and graft failure in adult liver transplant recipients, Dig Dis Sci, vol.58, issue.3, pp.824-834, 2013. ,
Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival, J Heart Lung Transplant, vol.34, issue.11, pp.1442-1448, 2015. ,
High withinpatient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation, Nephrol Dial Transplant, vol.25, issue.8, pp.2757-2763, 2010. ,
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients, American Journal of Transplantation, vol.16, issue.10, pp.2954-2963, 2016. ,
, Annual Data Report: Kidney, 2017.
, Am J Transplant, vol.19, issue.2, pp.19-123, 2019.
The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? Advances in Chronic Kidney Disease, vol.27, pp.56-66, 2020. ,
,
, Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation, Ther Drug Monit, vol.37, issue.5, pp.560-567, 2015.
Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction, American Journal of Transplantation, vol.15, issue.10, pp.2726-2731, 2015. ,
Effects of Cyclosporine on the Renin-Angiotensin-Aldosterone System and Potassium Excretion in Renal Transplant Recipients, Arch Intern Med, vol.145, issue.3, pp.505-508, 1985. ,
Potassium Modulates Electrolyte Balance and Blood Pressure through Effects on Distal Cell Voltage and Chloride, Cell Metabolism, vol.21, issue.1, pp.39-50, 2015. ,
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension, Nat Med, vol.17, issue.10, pp.1304-1309, 2011. ,
Evidence that the inhibition of Na+/K+-ATPase activity by FK506 involves calcineurin, Kidney International, vol.46, issue.3, pp.647-652, 1994. ,
Downregulation of Ca2+ and Mg2+ Transport Proteins in the Kidney Explains Tacrolimus (FK506)-Induced Hypercalciuria and Hypomagnesemia, JASN, vol.15, issue.3, pp.549-557, 2004. ,
Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats, Clin Sci (Lond), vol.75, issue.5, pp.509-514, 1988. ,
Hyperuricemia at 1 Year After Renal Transplantation, Its Prevalence, Associated Factors, and Graft Survival, Transplantation, vol.94, issue.2, pp.145-151, 2012. ,
Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014), Am J Nephrol, vol.48, issue.6, pp.472-481, 2018. ,
Inhibition of calcineurin phosphatase promotes exocytosis of renin from juxtaglomerular cells, Kidney International, vol.77, issue.2, pp.110-117, 2010. ,
Lipid Profile During Azathioprine or Mycophenolate Mofetil Combinations With Cyclosporine and Steroids, Transplantation Proceedings, vol.39, issue.1, pp.135-137, 2007. ,
Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels, JAMA, vol.262, issue.1, pp.53-56, 1989. ,
Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma, International Journal of Pharmaceutics, vol.358, issue.1, pp.219-223, 2008. ,
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients, Cochrane Database of Systematic Reviews, issue.4, 2005. ,
Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell, Transplantation, vol.59, issue.11, pp.1606-1613, 1995. ,
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation1, Transplantation, vol.63, issue.7, pp.977-983, 1997. ,
Neurotoxicity of calcineurin inhibitors: impact and clinical management, Transplant International, vol.13, issue.5, pp.313-326, 2000. ,
Neurotoxicity of immunosuppressive drugs, Liver Transplantation, vol.7, issue.11, pp.937-942, 2001. ,
Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes, American Journal of Physiology-Cell Physiology, vol.284, issue.6, pp.1593-1603, 2003. ,
Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients, Transplantation, vol.80, issue.11, pp.1546-1549, 2005. ,
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation, Ther Drug Monit, vol.31, issue.4, pp.416-435, 2009. ,
, Association internationale de surveillance thérapeutique des médicaments et de toxicologie clinique, 2020.
Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation, Am J Transplant, vol.9, issue.8, pp.1876-1885, 2009. ,
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report, Therapeutic Drug Monitoring, vol.41, issue.3, pp.261-307, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02150345
Estimating blood volume in obese and morbidly obese patients, Obes Surg, vol.16, issue.6, pp.773-776, 2006. ,
Cardiac function in massively obese patients and the effect of weight loss, Can J Surg, vol.34, issue.5, pp.431-434, 1991. ,
Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity, Cardiovasc Res Cent Bull, vol.1, pp.39-44, 1962. ,
Lipomatous infiltrates of the heart, Arch Pathol Lab Med, vol.102, issue.2, pp.69-72, 1978. ,
Cardiac conduction system involvement in sudden death of obese young people, Am Heart J, vol.129, issue.2, pp.273-281, 1995. ,
The effects of body mass index on lung volumes, Chest, vol.130, issue.3, pp.827-833, 2006. ,
Obstructive sleep apnoea syndrome in morbidly obese patients, J Intern Med, vol.230, issue.2, pp.125-129, 1991. ,
Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test, Int J Obes Relat Metab Disord, vol.24, issue.6, pp.772-776, 2000. ,
Anesthesia in the obese patient: pharmacokinetic considerations, J Clin Anesth, vol.17, issue.2, pp.134-145, 2005. ,
Effects of obesity on the cytochrome P450 enzyme system, Int J Clin Pharmacol Ther, vol.37, issue.1, pp.8-19, 1999. ,
Glomerular filtration rate in severely overweight normotensive humans, Am J Kidney Dis, vol.35, issue.6, pp.1144-1148, 2000. ,
Lean body mass normalizes the effect of obesity on renal function, British Journal of Clinical Pharmacology, vol.65, issue.6, pp.964-965, 2008. ,
Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril, Am J Physiol, vol.263, issue.3, pp.496-502, 1992. ,
Effects of genetic obesity on renal structure and function in the Zucker rat, J Lab Clin Med, vol.106, issue.5, pp.598-604, 1985. ,
Gastric emptying of solids and semi-solids in morbidly obese and non-obese subjects: an assessment using the 13C-octanoic acid and 13C-acetic acid breath tests, Obes Surg, vol.17, issue.2, pp.236-241, 2007. ,
Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors, Clin Nutr, vol.31, issue.5, pp.735-740, 2012. ,
Alterations of gastrointestinal motility in obesity, Obes Res, vol.12, issue.11, pp.1723-1732, 2004. ,
Preliminary studies on the gastrointestinal responses to fatty meals in obese people, Int J Obes Relat Metab Disord, vol.17, issue.5, pp.295-300, 1993. ,
Gastrointestinal function in obesity: motility, secretion, and absorption following a liquid test meal, Metab Clin Exp, vol.41, issue.4, pp.390-395, 1992. ,
Gut Microbiota and Obesity, Curr Obes Rep, vol.1, issue.1, pp.1-8, 2012. ,
Influence of obesity on drug disposition, Clin Pharm, vol.6, issue.9, pp.706-714, 1987. ,
A comparison of the pharmacokinetics of propranolol in obese and normal volunteers, Br J Clin Pharmacol, vol.21, issue.5, pp.529-532, 1986. ,
Trazodone kinetics: effect of age, gender, and obesity, Clin Pharmacol Ther, vol.42, issue.2, pp.193-200, 1987. ,
Effect of age, gender, and obesity on midazolam kinetics, Anesthesiology, vol.61, issue.1, pp.27-35, 1984. ,
Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients, J Antimicrob Chemother, vol.66, issue.10, pp.2330-2335, 2011. ,
The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients, Transplantation, vol.47, issue.5, pp.806-810, 1989. ,
The pharmacokinetics of dexfenfluramine in obese and non-obese subjects, Br J Clin Pharmacol, vol.39, issue.6, pp.684-687, 1995. ,
Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers, Clin Pharmacokinet, vol.53, issue.10, pp.931-941, 2014. ,
Adaptation posologique chez le sujet obèse, Réanimation, vol.24, issue.4, pp.367-378, 2015. ,
Particularités pharmacocinétiques chez le patient obèse, Réanimation, vol.15, issue.6, pp.427-432, 2006. ,
Implications of Obesity for Drug Therapy: Limitations and Challenges, Clinical Pharmacology & Therapeutics, vol.90, issue.1, pp.77-89, 2011. ,
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients, Clin Pharmacokinet, vol.50, issue.11, pp.739-750, 2011. ,
An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children, CPT Pharmacometrics Syst Pharmacol, vol.2, p.73, 2013. ,
Drug Disposition in Obesity: Toward Evidence-Based Dosing, Annual Review of Pharmacology and Toxicology, vol.55, issue.1, pp.149-167, 2015. ,
Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis, J Antimicrob Chemother, vol.69, issue.3, pp.715-723, 2014. ,
Pharmacokinetics and protein binding of cefazolin in morbidly obese patients, Eur J Clin Pharmacol, vol.67, issue.10, pp.985-992, 2011. ,
Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients, OBES SURG, vol.22, issue.5, pp.791-796, 2012. ,
Estimating blood volume in obese and morbidly obese patients, Obes Surg, vol.16, issue.6, pp.773-776, 2006. ,
Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients, Br J Clin Pharmacol, vol.71, issue.1, pp.34-40, 2011. ,
Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen, J Lab Clin Med, vol.101, issue.6, pp.873-880, 1983. ,
Effect of obesity on the pharmacokinetics of drugs in humans, Clin Pharmacokinet, vol.49, issue.2, pp.71-87, 2010. ,
Impact of obesity on drug metabolism and elimination in adults and children, Clin Pharmacokinet, vol.51, issue.5, pp.277-304, 2012. ,
Vancomycin dosing in morbidly obese patients, Eur J Clin Pharmacol, vol.54, issue.8, pp.621-625, 1998. ,
The mechanism of renal clearance of cisplatin (cisdichlorodiammine platinum ii) and its modification by furosemide and probenecid, Biochem Pharmacol, vol.31, issue.13, pp.2243-2246, 1982. ,
Intravenous ciprofloxacin disposition in obesity, Clin Pharmacol Ther, vol.54, issue.4, pp.368-373, 1993. ,
Keeping the young-elderly healthy: is it too late to improve our health through nutrition?, Am J Clin Nutr, vol.86, issue.5, pp.1572-1576, 2007. ,
Morbid Obesity: Peri-Operative Management, 2004. ,
Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known, Arch Intern Med (Chic) ,
, , pp.863-871
Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey, J Oncol Pract, vol.4, issue.3, pp.108-113, 2008. ,
Gentamicin therapy, Drug Intell Clin Pharm, vol.8, pp.650-655, 1974. ,
What is the best size descriptor to use for pharmacokinetic studies in the obese?, Br J Clin Pharmacol, vol.58, issue.2, pp.119-133, 2004. ,
Caution when lean body weight is used as a size descriptor for obese subjects, Clin Pharmacol Ther, vol.72, issue.6, pp.743-744, 2002. ,
Quantification of lean bodyweight, Clin Pharmacokinet, vol.44, issue.10, pp.1051-1065, 2005. ,
Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients, Eur J Clin Pharmacol, vol.24, issue.5, pp.643-647, 1983. ,
A standard weight descriptor for dose adjustment in the obese patient, Clin Pharmacokinet, vol.43, issue.15, pp.1167-1178, 2004. ,
Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, Int J Med Sci, vol.10, issue.12, pp.1665-1673, 2001. ,
Modifications pharmacocinétiques chez les sujets obèses ou ayant bénéficié d'une chirurgie bariatrique : application aux immunosuppresseurs ,
Obésité et accès à la greffe rénale parmi des patients démarrant une dialyse : une étude de cohorte prospective, Néphrologie & Thérapeutique, vol.12, issue.5, p.281, 2016. ,
Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, vol.13, 2015. ,
Influence of overweight on survival of kidney transplant, Nephrol Dial Transplant, vol.12, issue.4, p.855, 1997. ,
Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index, Transplantation Proceedings, vol.33, issue.7-8, pp.3110-3111, 2001. ,
The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation, Eur J Clin Pharmacol, vol.68, issue.5, pp.671-680, 2012. ,
Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants., Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants, Kidney Res Clin Pract, vol.31, pp.157-162, 2012. ,
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects, Clin Pharmacol Ther, vol.93, issue.3, pp.275-282, 2013. ,
Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients, Expert Opinion on Drug Metabolism & Toxicology, vol.13, issue.12, pp.1225-1236, 2017. ,
Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres, Liver Transpl, vol.10, issue.3, pp.392-396, 2004. ,
Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction? ,
No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients, Transplantation Proceedings, vol.50, issue.6, pp.1755-1759, 2018. ,
A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients, Clinical Transplantation, vol.0, issue.0, p.13640 ,